Cortechs.ai | NeuroQuant PET

Rapid, automated subregional tracer quantification

This research-specific tool provides researchers and physicians with a cutting-edge solution for the study of frontotemporal dementia and Alzheimer’s disease.

Research Use Only - Not FDA Cleared

Cortechs.ai|NeuroQuant PET
Cortechs.ai|NeuroQuant PET
Cortechs.ai|NeuroQuant PET

Insight that leads to breakthrough discoveries

Automatically quantify PET tracer bindings localized to brain structures identified by NeuroQuant® 3D T1 MRI segmentation. Select between amyloid tau and FDG tracers for visual and statistical (Z-score) comparisons of each normalized regional PET tracer value to normative population data.

Benefits

Cortechs.ai|NeuroQuant PET

Reporting options

Choice of reports corresponding to PET tracer used

Cortechs.ai|NeuroQuant PET

Clear visualization

Color-coded, graphical reports simplify quantitative reads

Cortechs.ai|NeuroQuant PET

24/7 access

Secure access to Cortechs.ai’s secure, cloud-based system from virtually anywhere

NeuroQuant® PET reports

Powered by NeuroQuant® for trusted and proven brain segmentation analysis.

Related insights

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

12/09/2025

Dementia Imaging: Case-based PET/MRI Approach

Join us for a webinar that will unlock the latest insights in dementia imaging with Dr. Ana M. Franceschi, MD PhD.

06/16/2025

Seeing Alzheimer’s More Clearly: How PET Imaging Is Changing the Game

PET imaging is transforming how we detect and monitor Alzheimer’s disease, enabling earlier diagnosis, better disease tracking, and more personalized treatment.
Scroll to Top